Business Context and Reporting Period
This Form 8-K Current Report was filed by Lipocine Inc. on March 18, 2014. The report addresses a specific corporate event regarding the listing status of the Company's common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing event and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the approval of Lipocine Inc.'s common stock for listing on the NASDAQ Capital Market. The Company expects trading to commence under the symbol "LPCN" on or about March 21, 2014.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the NASDAQ listing approval. The filing does not provide specific financial guidance, outlook projections, or a discussion of risks and contingencies beyond the event itself.
Investor Verification Checklist
- Verify the commencement of trading on the NASDAQ Capital Market on or about March 21, 2014.
- Confirm the continued use of the ticker symbol "LPCN".
- Review the attached press release (Exhibit 99.1) for additional details on the listing approval.